The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Is PGEN a good stock to buy? We came across a bullish thesis on Precigen, Inc. on Valueinvestorsclub.com by coalone. In this article, we will summarize the bulls’ thesis on PGEN. Precigen, Inc.'s share was trading at $4.0200 as of April 28th. PGEN’s forward P/E was 9.14 according to Yahoo Finance.

Pressmaster/Shutterstock.com

Precigen (PGEN) is a biotechnology company that has transitioned from a clinical-stage developer to a commercial rare disease platform following the August 2025 approval of Papzimeous for recurrent respiratory papillomatosis, positioning it as a newly commercial asset with significant re-rating potential as launch execution unfolds.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The drug targets a 27,000-patient US RRP population and carries a $460,000 four-dose regimen delivered via buy-and-bill channels, but the early launch phase is constrained by insurance coverage variability, hospital onboarding, and reimbursement friction despite strong physician enthusiasm.

Market expectations appear significantly misaligned with real-world adoption, as care is concentrated in 100–150 specialist clinics treating a large share of high-severity patients, enabling efficient education and rapid protocol adoption supported by KOL advocacy and increasing appeal success rates. Modeling suggests only a fraction of patients are currently treated, yet conservative projections indicate roughly 1,600–1,700 patients in 2026 and nearly 3,000 in 2027, with dosing-based revenue recognition driving pronounced quarterly volatility and setting up for significant revenue surprises.

This dynamic supports expectations for outsized quarterly beats of 100%+ to 300%+ in 2026, potential EPS inflection into profitability, and multiple valuation frameworks converging on substantial upside through SOTP rerating, forward earnings expansion, and NPV-based long-term cash flow potential across RRP and HPV indications.

Strategically, the platform also embeds meaningful acquisition optionality, with large-cap pharma such as Merck viewed as potential acquirers given HPV oncology expansion, ex-US commercialization leverage, and manufacturing scale, supporting a long-term takeout narrative potentially valuing the company near $20 per share by 2027 target premium.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy-driven commercialization, gene-editing pipeline optionality, and strong reimbursement progress supporting multi-billion-dollar long-term upside. CRSP’s stock price has appreciated by approximately 27.06% since our coverage. Magnus Ofstad shares a similar view but emphasizes Sarepta Therapeutics’ (SRPT) acquisition-driven rerating potential within rare disease leadership.

Precigen, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 19 hedge fund portfolios held PGEN at the end of the fourth quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of PGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PGEN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.